Draft:Boundless Bio

Boundless Bio Announces Poster Presentation at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting

Retrieved on: 
Wednesday, October 21, 2020
Biotechnology, General Health, Health, Genetics, Oncology, DNA, Medicine, Health, Clinical medicine, Carcinogenesis, Oncology, Extrachromosomal DNA, Draft:Boundless Bio, Cancer, Oncogene, Tumour heterogeneity, Extrachromosomal circular DNA, ecDNA, Boundless Bio

Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.

Key Points: 
  • Extrachromosomal DNA, or ecDNA, are distinct circular units of DNA containing functional genes, including oncogenes, that are separated from tumor cell chromosomes.
  • ecDNA rapidly replicate within cancer cells, causing high numbers of oncogene copies and can be passed to daughter cells asymmetrically during cell division, driving tumor heterogeneity.
  • They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

Boundless Bio to Present at the Citi 15th Annual BioPharma Virtual Conference

Retrieved on: 
Thursday, September 3, 2020
Oncology, Health, Genetics, Other Health, Pharmaceutical, Biotechnology, DNA, Draft:Boundless Bio, Extrachromosomal DNA, Cancer, Oncology, Boundless

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a corporate overview at Citis 15th Annual BioPharma Virtual Conference.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a corporate overview at Citis 15th Annual BioPharma Virtual Conference.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005213/en/

Boundless Bio Announces Publication in Nature Genetics Detailing the Association Between Extrachromosomal DNA-Based Oncogene Amplification and Poor Cancer Outcomes

Retrieved on: 
Monday, August 17, 2020
Genetics, Health, Oncology, DNA, Draft:Boundless Bio, Branches of biology, Medical genetics, Extrachromosomal DNA, Biology, Applied genetics, Biotechnology, Cancer, Oncogenomics, ecDNA, Boundless Bio, Boundless Bio’s Spyglass™ Platform

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.

Key Points: 
  • Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced research published in the journal Nature Genetics that demonstrates that ecDNA-based oncogene amplification drives poor outcomes for patients across many cancer types.
  • Ludwig Professor of Cancer Genomics and Genetics, Stanford University; and Roel Verhaak, Ph.D., Professor and Associate Director of Computational Biology, The Jackson Laboratory.
  • In addition, patients whose cancers carried ecDNA had significantly shorter survival, even when controlled for tissue type, than patients whose cancers were not driven by ecDNA-based oncogene amplification.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.